Evaluation and Validation of Novel Diagnostic Tool for Allergists (AbioSCOPE)

Exclusion Criteria

• •Presence of positive HIV-1 viremia by the ultra-sensitive method in the 12 months preceding the study.
• •Use of any investigational or non-registered product (drug or vaccine)
• •Chronic administration (more than 14 days) of immunosuppressive or immunomodulatory drugs in the 6 months preceding the study for corticosteroids. This means a dose of Prednisone or equivalent substance greater than or equal to 0.5 mg per kg / day. Inhaled topical steroids are allowed.
• •Administration of any immunoglobulin, any immunotherapy or administration of some blood products in the 3 months preceding the study, or planned during the study period.
• •Any health condition or patient history, in the opinion of the investigator, could interfere with the evaluation of the study's objectives.
• •Participation in another experimental protocol during the period of the study.
• •Demonstration, confirmation or suspicion of a condition of immunosuppression or immunodeficiency (including HIV infection) based on medical history and physical examination (no laboratory test).
• •A family history of congenital or hereditary immunodeficiency.
• •Subjects taking any of the following medications: antihistamines in the week preceding the consultation, systemic steroids (inhaled or nasal steroids are allowed), anti-cytokines or cytokines, systemic interferon (injection local interferon α for the treatment of HPV is allowed) or treated with systemic chemotherapy.